Background
Methods
Patient population and samples
Receptor status evaluation and molecular subtypes classification
Statistical analysis
Results
Patient characteristics
Characteristic | No. | % |
---|---|---|
Age, years
| 54 (24-91) | |
Menstrual status
| ||
Peri/pre-menopause | 98 | 32.9 |
Post-menopause | 200 | 67.1 |
Breast surgery type
| ||
Mastectomy (+/-reconstruction) | 259 | 86.9 |
Lumpectomy | 39 | 13.1 |
Tumor size
| ||
Tx | 7 | 2.3 |
≤2 cm | 123 | 41.3 |
2-5 cm | 160 | 53.7 |
>5 cm | 8 | 2.7 |
Axillary lymph node
| ||
Negative | 165 | 55.4 |
1-3 + | 76 | 25.5 |
≥4+ | 55 | 18.5 |
Nx | 2 | 0.7 |
Characteristic | No. (%) | P value | |
---|---|---|---|
CNB | OEB | ||
Pathological type
| 0.190 | ||
Invasive ductal carcinoma | 260 (87.2) | 269 (90.3) | |
Invasive lobular carcinoma | 12 (4.0) | 11 (3.7) | |
Mixed carcinoma | 11 (3.7) | 3 (1.0) | |
Others | 15 (5.0) | 15 (5.0) | |
Histological grading
| 0.009 | ||
I | 6 (2.0) | 4 (1.3) | |
II | 138 (46.3) | 151 (50.7) | |
III | 97 (32.6) | 114 (38.3) | |
NA | 57 (19.1) | 29 (9.7) | |
Estrogen Receptor
| 0.294 | ||
Negative | 67 (22.5) | 78 (26.2) | |
Positive | 231 (77.5) | 220 (73.8) | |
Progesterone Receptor
| 0.502 | ||
Negative | 120 (40.3) | 112 (37.6) | |
Positive | 178 (59.7) | 186 (62.4) | |
HER2
| 0.768 | ||
Negative | 233 (78.2) | 230 (77.2) | |
Positive | 65 (21.8) | 68 (22.8) | |
Ki67 (%, mean)
| 26.8 (1-90) | 29.3 (1-90) | 0.046 |
<14 | 112 (37.6) | 89 (29.9) | |
≥14 | 186 (62.4) | 209 (70.1) | |
Hormonal receptor
| 0.386 | ||
Negative | 66 (22.1) | 75 (25.2) | |
Positive | 232 (77.9) | 223 (74.8) | |
Molecular subtype
| 0.484* | ||
Luminal A | 97 (32.6) | 80 (26.8) | |
Luminal B | 135 (45.4) | 143 (48.0) | |
Luminal B (HER2-) | 97 (32.6) | 105 (35.2) | |
Luminal-HER2+ | 38 (12.8) | 38 (12.8) | |
Triple negative | 39 (13.1) | 45 (15.1) | |
HER2 positive | 27 (9.1) | 30 (10.1) |
Comparison of CNB with OEB for receptor status and Ki67 results
CNB | OEB | Concordance rate (%) | Kappa | P value | |
---|---|---|---|---|---|
Negative | Positive | ||||
ER
| 93.6 |
0.827
|
<0.001
| ||
Negative | 63 | 4 | |||
Positive | 15 | 216 | |||
PgR
| 85.9 |
0.704
|
<0.001
| ||
Negative | 95 | 25 | |||
Positive | 17 | 161 | |||
HER2
| 96.3 |
0.894
|
<0.001
| ||
Negative | 226 | 7 | |||
Positive | 4 | 61 | |||
Ki67
| <14% | ≥14% | 79.5 |
0.545
|
<0.001
|
<14% | 70 | 42 | |||
≥14% | 19 | 167 | |||
HR
| 93.6 |
0.824
|
<0.001
| ||
Negative | 61 | 5 | |||
Positive | 14 | 218 |
Comparison of CNB with OEB for molecular subtypes
CNB | OEB | Concordance rate (%) | Kappa | ||||
---|---|---|---|---|---|---|---|
(P value) | |||||||
Using Ki67 = 14% as cutoff value for determining Luminal A and B in HR+/HER2- diseases
| |||||||
4 Subtypes
| Luminal A | Luminal B | TNBC | HER2+ |
77.2
|
0.658 (<0.001)
| |
Luminal A | 65 | 32 | 0 | 0 | |||
Luminal B | 15 | 106 | 7 | 7 | |||
TNBC | 0 | 1 | 37 | 1 | |||
HER2+ | 0 | 4 | 1 | 22 | |||
5 Subtypes
| Luminal A | Luminal B | TNBC | HER2+ |
75.8
|
0.679 (<0.001)
| |
HER2- | HER2+ | ||||||
Luminal A | 65 | 31 | 1 | 0 | 0 | ||
Luminal B | |||||||
HER2- | 14 | 72 | 3 | 7 | 1 | ||
HER2+ | 1 | 1 | 30 | 0 | 6 | ||
TNBC | 1 | 0 | 0 | 37 | 1 | ||
HER2+ | 0 | 0 | 4 | 1 | 22 | ||
Using Ki67 = 20% as cutoff value for determining Luminal A and B in HR+/HER2- diseases
| |||||||
4 Subtypes
| Luminal A | Luminal B | TNBC | HER2+ |
79.2
|
0.692 (<0.001)
| |
Luminal A | 110 | 31 | 0 | 0 | |||
Luminal B | 10 | 67 | 7 | 7 | |||
TNBC | 1 | 0 | 37 | 1 | |||
HER2+ | 0 | 4 | 1 | 22 | |||
5 Subtypes
| Luminal A | Luminal B | TNBC | HER2+ |
78.2
|
0.699 (<0.001)
| |
HER2- | HER2+ | ||||||
Luminal A | 110 | 29 | 2 | 0 | 0 | ||
Luminal B | |||||||
HER2- | 9 | 34 | 2 | 7 | 1 | ||
HER2+ | 1 | 1 | 30 | 0 | 6 | ||
TNBC | 1 | 0 | 0 | 37 | 1 | ||
HER2+ | 0 | 0 | 4 | 1 | 22 |